A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

Open-Label Phase 3 Long-Term Safety Study of Migalastat

NCT01458119 ·Status: TERMINATED ·Phase: PHASE3

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

NCT02194985 ·Status: COMPLETED ·Phase: PHASE3

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

NCT01196871 ·Status: COMPLETED ·Phase: PHASE2

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

NCT01476163 ·Status: AVAILABLE

A Study of Patients With Fabry Disease (US Specific)

NCT06906367 ·Status: RECRUITING

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

NCT01218659 ·Status: COMPLETED ·Phase: PHASE3

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

NCT04049760 ·Status: COMPLETED ·Phase: PHASE3

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

NCT06904261 ·Status: RECRUITING ·Phase: PHASE3

German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.

NCT03135197 ·Status: COMPLETED

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

NCT03500094 ·Status: COMPLETED ·Phase: PHASE3

Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity

NCT00106912 ·Status: COMPLETED

A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

NCT01853852 ·Status: COMPLETED ·Phase: PHASE1

A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

NCT00875160 ·Status: TERMINATED ·Phase: PHASE1

A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

NCT00433147 ·Status: COMPLETED ·Phase: PHASE2

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

NCT06858397 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients

NCT00813865 ·Status: COMPLETED ·Phase: PHASE2

French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat

NCT04602364 ·Status: COMPLETED

Study of STG-001 in Subjects With Stargardt Disease

NCT04489511 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension

NCT02531217 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease

NCT00446550 ·Status: COMPLETED ·Phase: PHASE2

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

NCT00074971 ·Status: COMPLETED ·Phase: PHASE3

MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study

NCT03683966 ·Status: UNKNOWN

Treatment Protocol of Replagal for Patients With Fabry Disease

NCT01031173 ·Status: NO_LONGER_AVAILABLE

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

NCT00081497 ·Status: COMPLETED ·Phase: PHASE4

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

NCT00140621 ·Status: COMPLETED ·Phase: PHASE4